Weight loss injections and insulin resistance: what the evidence shows

The biological link between insulin resistance and body weight

Insulin resistance and excess adiposity tend to reinforce each other. When cells become less responsive to insulin, the pancreas produces more of it to compensate, and elevated insulin itself promotes fat storage, particularly around the abdomen. That stored fat, especially visceral fat, then secretes inflammatory signals that worsen insulin sensitivity further. It is a self-sustaining loop.

GLP-1 medicines interrupt it at several points. By slowing gastric emptying, they reduce the sharp post-meal glucose spikes that demand large insulin surges. By acting on the hypothalamus, they reduce appetite and overall calorie intake, so less fat accumulates. And as fat mass falls, insulin sensitivity tends to recover. The NHS overview of tirzepatide on the NHS medicines pages describes this dual appetite-and-glucose mechanism clearly.

Tirzepatide adds a second layer. Its GIP receptor activity appears to enhance insulin secretion in response to meals and may improve how fat cells respond to insulin signalling directly. That is the mechanistic reason researchers expected (and found) strong metabolic improvements alongside the weight loss in SURMOUNT-1.

What the trial data recorded on insulin resistance specifically

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes. At 72 weeks, the highest active doses produced average weight loss of around 20–21% of baseline body weight. Alongside that, participants showed marked reductions in fasting insulin, fasting glucose and HOMA-IR, the standard calculated index of insulin resistance. These were not incidental findings; they were pre-specified endpoints.

Semaglutide's STEP 1 trial (68 weeks, 2.4mg) produced average weight loss of around 15%, again with accompanying improvements in glucose regulation and insulin markers. The head-to-head SURMOUNT-5 trial, published in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg in adults with obesity and no diabetes, relevant context if you are specifically trying to address insulin resistance, since the degree of metabolic improvement tends to track with the degree of weight reduction.

Neither set of results means everyone achieves that average. Responses vary. Individual suitability (including any existing diabetes diagnosis) shapes both which medicine a prescriber reaches for and what realistic progress looks like. Our clinical team reviews every consultation before any prescription is written.

Who these injections are and are not licensed for in the UK

Mounjaro (tirzepatide) and Wegovy (semaglutide) are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition. Prediabetes and early insulin resistance without a formal type 2 diabetes diagnosis can sit within the eligibility picture, though the prescriber weighs the full clinical history, not the BMI figure alone. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

People who already have a type 2 diabetes diagnosis are treated differently in licensing terms: tirzepatide also holds a UK licence for type 2 diabetes management under the Mounjaro brand, but the dose schedules and clinical targets differ. Ozempic is semaglutide licensed for type 2 diabetes, not weight loss, the two should never be conflated. If you have existing diabetes, your prescriber needs to know before any weight-management prescription is considered.

People under 18, those who are pregnant, breastfeeding, or actively trying to conceive are not candidates for these medicines. Certain thyroid and pancreatic histories also require careful screening. The page on side effects of weight loss injections covers the clinical cautions in more detail, including the January 2026 MHRA Drug Safety Update on pancreatitis.

Practical realities: prescription, access and what comes next

Both medicines are prescription-only in the UK. That means a qualified prescriber (not a questionnaire or an automated system) must clinically assess you first. At nume, a GPhC-registered Independent Prescriber reads your consultation the same day it arrives. If you order before noon on a working day and the prescriber approves your treatment, your medicine is dispatched the same day and arrives via tracked DPD delivery the next working day, in plain packaging.

If you are curious about what the medicines cost privately, the cost of weight loss injections in the UK page sets out the market context honestly, including what a legitimate price actually covers and why very low prices warrant caution. Fake pens carrying no active ingredient, or the wrong one, have been seized by the MHRA in significant quantities; the supply chain matters as much as the medicine itself.

Some people wonder about NHS access. NICE recommended tirzepatide in December 2024 (TA1026), and the NHS is rolling it out in phases based on BMI and comorbidities, but the criteria are strict and availability varies. For people who do not meet the current NHS thresholds, or who would rather not wait, a private prescription through a regulated pharmacy is the alternative route. If you want to understand how these medicines work as a treatment approach, our guide to insulin injections for weight loss walks through the options in plain language. The weight loss injection overview explains both paths without steering you toward one. And if needles are a concern, it is worth knowing that non-injection options exist, oral weight loss medicines are a growing category, including the newly approved Wegovy tablet.

Monday mornings tend to be our busiest consultation window, people reflect over the weekend and act at the start of the week. Whether you have a holiday coming up (travel with these medicines is straightforward, with a letter from your prescriber), or you want to start before the month turns, the consultation itself takes a few minutes and there is no obligation. Check your eligibility with our prescribers whenever you are ready.